The Pharmacy Times® Oncology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
Because of the vulnerabilities of CDK4/6i-resistant tumors, researchers believe that it is imperative to improve the survival of this group of patients.
The rise in value-based reimbursement models has required oncology care providers to assume an unprecedented level of accountability.
The decline in the cancer mortality rate attributed to immunotherapy methods, early detection, and treatment.
Maurie Markman, MD, leads a discussion on the design and results of the PRIMA trial, and how it has impacted practice.
After injecting the flu vaccine into a tumor cell, researchers found that the injection either slowed the growth or shrunk the tumor itself.
Key opinion leaders discuss the importance of HRD testing, with special consideration of tissue testing versus somatic testing.
This medication is the first precision therapy approved to treat a genomically defined population of patients with GIST, according to Blueprint Medicines.
Officials with the FDA have approved pembrolizumab (Keytruda, Merck) for the treatment of certain patients with Bacillus Calmette-Guerin-unresponsive, high-risk, non-muscle invasive bladder cancer.
An effective treatment plan for squamous cell carcinoma best undertaken by a group of practitioners.
Since 2004, the FDA has approved different treatments for advanced prostate cancer, adding almost 2-3 indications per year for the past 15 years.
A study suggests that even brief art-making interventions can be beneficial for stressed caregivers of patients with cancer.
According to the study authors, such “anti-austerity agents” represent a promising approach to cancer chemotherapy.